1 / 6

Ewing Sarcoma Pipeline Assessment Review H1 2015

This report gives far reaching data on the restorative improvement for Ewing Sarcoma, complete with relative investigation at different stages, therapeutics appraisal by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent upgrades, and included news and press discharges. It additionally audits key players included in the remedial improvement for Ewing Sarcoma and uncommon components on late-stage and suspended tasks.

jack2222simon
Download Presentation

Ewing Sarcoma Pipeline Assessment Review H1 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ewing Sarcoma Pipeline Review H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 10-Jun-2015 No. of pages: 138 Single User License: US $2000 Browse more Reports on Cancer Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Ewing Sarcoma Pipeline Review H1 2015 This report gives far reaching data on the restorative improvement for Ewing Sarcoma, complete with relative investigation at different stages, therapeutics appraisal by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent upgrades, and included news and press discharges. It additionally audits key players included in the remedial improvement for Ewing Sarcoma and uncommon components on late-stage and suspended tasks. The report upgrades choice making capacities and help to make successful counter systems to increase upper hand. It fortifies R&D pipelines by recognizing new targets and MOAs to create first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Ewing Sarcoma Pipeline Review H1 2015 Companies Discussed/Mentioned in this Research : 3B Pharmaceuticals GmbH, Amgen Inc., Cebiotex, S.L., EntreChem, S.L., Exelixis, Inc., Gradalis Inc., Kolltan Pharmaceuticals, Inc., Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Novartis AG, Oncomatrix, S.L., Recombio S.L, Shionogi & Co., Ltd., Sigma-Tau S.p.A. and Tesaro, Inc. Drugs Profile Discussed in this Research : 3BP-227, cabozantinib s-malate, cancer vaccine, CEB-01 celyvir, dactinomycin next generation, Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology, EC-8042, EC-8105, everolimus, ganitumab, irinotecansucrosofate liposomal, KIT-SG3227, Monoclonal Antibody Conjugated for Ewing Sarcoma, Monoclonal Antibody to Inhibit GD2 for Oncology, MTX2-NIG, niraparib, pazopanib hydrochloride pembrolizumab, racotumomab, S-588410, SP-2509 and SST-0001 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Ewing Sarcoma Pipeline Review H1 2015 Scope For Ewing Sarcoma Pipeline Review H1 2015 • The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Ewing Sarcoma Pipeline Review H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Ewing Sarcoma Pipeline Review H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related